- Poster presentation
- Open Access
A universal monoclonal antibody protects against all influenza A and B viruses by targeting a highly conserved epitope in the viral neuraminidase
BMC Genomicsvolume 15, Article number: P8 (2014)
Hemagglutinin (HA) and neuraminidase (NA) are the two major surface glycoproteins of influenza viruses and the main targets of vaccine-induced antibodies (Abs). While several broadly neutralizing Abs targeting conserved epitopes in diverse HA subtypes have been isolated, NA-specific Abs could only cross-protect partially against homologous and heterologous strains from the same subtype.
Materials and methods
Comprehensive bioinformatics analyses of all publicly available full-length NA sequences using multiple alignments and Shannon entropy were conducted to identify conserved sequences in all influenza A and B viral NA . Growth kinetics of wild-type or recombinant viruses with single alanine substitutions within the identified regions was then analyzed in MDCK cells. A rabbit monoclonal Ab (mAb), denoted as HCA-2, raised against one of the characterized sequences was then examined for its in vitro inhibitory effects and in vivo prophylactic efficacy against several influenza A and B strains.
Bioinformatics analyses uncovered a universally conserved 9-mer peptide amongst all influenza NA proteins (amino acids 222-230 and comprised of “ILRTQESEC”). Substitutions within this universal epitope underscored its crucial roles in viral fitness and replication . Importantly, the HCA-2 mAb showed broad in vitro inhibition against multiple strains from all influenza A NA subtypes (N1-N9) and influenza B viruses from both Victoria and Yamagata genetic lineages [3, 4]. It also provided heterosubtypic protection in mice against lethal doses of H1N1 and H3N2 strains. Finally, amino acid residues I222 and E227, located in close proximity to the active site, were found to be indispensable for inhibition by this mAb [3, 4].
These findings reveal the essential role of this unique highly-conserved sequence in NA function and viral replication and indicate that it is sufficiently exposed to allow access by inhibitory antibody during the course of infection. Thus, it could represent a potential target for novel antivirals or targeted-vaccines against diverse strains of influenza A and B viruses.
Gravel C, Li C, Wang J, Hashem AM, Jaentschke B, Xu KW, Lorbetskie B, Gingras G, Aubin Y, Van Domselaar G, Girard M, He R, Li X: Qualitative and quantitative analyses of virtually all subtypes of influenza A and B viral mneuraminidases using antibodies targeting the universally conserved sequences. Vaccine. 2010, 28 (36): 5774-5784.
Doyle TM, Jaentschke B, Van Domselaar G, Hashem AM, Farnsworth A, Forbes NE, Li C, Wang J, He R, Brown EG, Li X: The universal epitope of influenza A viral neuraminidase fundamentally contributes to enzyme activity and viral replication. J Biol Chem. 2013, 288 (25): 18283-18289.
Doyle TM, Hashem AM, Li C, Van Domselaar G, Larocque L, Wang J, Smith D, Cyr T, Farnsworth A, He R, Hurt AC, Brown EG, Li X: Universal anti-neuraminidase antibody inhibiting all influenza A subtypes. Antiviral Res. 2013, 100 (2): 567-574.
Doyle TM, Li C, Bucher DJ, Hashem AM, Van Domselaar G, Wang J, Farnsworth A, She Y-M, Cyr T, He R, Brown EG, Hurt AC, Li X: A monoclonal antibody targeting a highly conserved epitope in influenza B neuraminidase provides protection against drug resistant strains. Biochem Biophys Res Commun. 2013, 441 (1): 226-229.